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Drugs targeting themitotic spindle are used extensively during chemotherapy, but surprisingly, little is known
about how they kill tumor cells. This is largely becausemany of the population-based approaches are indirect
and lead to vague and confusing interpretations. Here, we use a high-throughput automated time-lapse light
microscopy approach to systematically analyze over 10,000 single cells from 15 cell lines in response to three
different classes of antimitotic drug. We show that the variation in cell behavior is far greater than previously
recognized, with cells within any given line exhibiting multiple fates. We present data supporting a model
wherein cell fate is dictated by two competing networks, one involving caspase activation, the other
protecting cyclin B1 from degradation.INTRODUCTION
Microtubule toxins are used extensively during chemotherapy,
demonstrating impressive efficacy in the treatment of breast
and ovarian cancer (Jordan and Wilson, 2004). In addition to kill-
ing tumor cells, these cytotoxins affect normal dividing cells,
causing myelosuppression (McGuire et al., 1989). While this
side effect is clinically manageable, more problematic are the
peripheral neuropathies caused by inhibiting microtubule dy-
namics in nondividing cells (Rowinsky et al., 1993).
To minimize neurotoxicity, new agents are being developed
that disrupt mitosis without affecting microtubules (Jackson
et al., 2007). Front-runners include Eg5 kinesin inhibitors and in-
hibitors of mitotic kinases, such as the Auroras and Plk1 (Keen
and Taylor, 2004; Bergnes et al., 2005; Strebhardt and Ullrich,
2006). Importantly, little peripheral neuropathy manifests in pa-
tients treated with Eg5 inhibitors (Tang et al., 2008; Lee et al.,
2008). Whether these new agents will exert significant antitumor
effects is currently under investigation.
A major unresolved issue is defining which tumors are likely to
respond to these new antimitotic agents; such knowledge wouldallow better design of clinical trials and pave the way for patient
stratification if the drugs demonstrate efficacy. Consequently,
extensive effort has been directed at understanding how
cultured tumor cells respond to antimitotic agents (Rieder and
Maiato, 2004; Weaver and Cleveland, 2005; Jackson et al.,
2007).
It is well established that antimitotic compounds activate the
spindle assembly checkpoint (SAC) leading to mitotic arrest
(Musacchio and Salmon, 2007). Following prolonged arrest,
a number of outcomes have been described. While some cells
appear to die in mitosis, others exit mitosis without dividing
and return to interphase (Rieder and Maiato, 2004; Weaver and
Cleveland, 2005). Once back in interphase, some lines undergo
cell-cycle arrest, others die, and others rereplicate their
genomes, i.e., endocycle.
Despite extensive effort, our understanding of the factors that
dictate cell fate following prolonged mitotic arrest is limited.
Efforts have been hampered because commonly used popula-
tion-based approaches, such as flow cytometry and western
blotting, generate indirect data that can be difficult to interpret
(Rieder andMaiato, 2004). In addition, different studies invariablySIGNIFICANCE
Although traditional antimitotic agents such as the taxanes show impressive clinical efficacy in the treatment of cancer, pe-
ripheral neurotoxicities caused by interfering with microtubule dynamics in nondividing cells is a limitation. A new genera-
tion of inhibitors that block mitosis without affecting microtubule dynamics are now being tested, the front-runners being
inhibitors of the Eg5 kinesin. However, we still have little understanding of the mechanisms that dictate cell fate in response
to either traditional antimitotic drugs or these new agents. Here, we take a systematic, single-cell-based approach to de-
scribe how different tumor cells respond to these drugs. The data set presented provides a resource and an intellectual
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How Cancer Cells Respond to Antimitotic Drugsuse different combinations of cell lines, drugs, and drug concen-
trations, so comparing data sets is difficult. Furthermore, the ter-
minology used is ambiguous; ‘‘slippage’’ and ‘‘adaptation’’ are
widely used to describe cell fate following prolonged arrest with-
out any clearly stated definitions.
There is evidence that cells can ‘‘slip’’ out of mitosis: in non-
transformed retinal pigment epithelial (RPE) cells, cyclin B1 is
gradually degraded during a protracted mitotic arrest, presum-
ably reaching a threshold no longer sufficient to maintain the
mitotic state, despite continued SAC signaling (Brito and Rieder,
2006). Based on this, it has been argued that vertebrate cells slip
but do not ‘‘adapt.’’ However, there are numerous reports indi-
cating that death can occur in mitosis (Sherwood et al., 1994;
Woods et al., 1995; Panvichian et al., 1998; Rieder and Maiato,
2004). Whether this also requires cyclin B1 levels to fall below
a certain threshold, as opposed to requiring induction of a sepa-
rate cell death pathway, is unclear.
To understand how human tumor cells respond to antimitotic
agents, we have taken a systematic approach. Using automated
time-lapse light microscopy, we established a single-cell-based
assay and analyzed over 10,000 cells from 15 cell lines in
response to different classes of antimitotic drugs. Our aim was
to generate a sufficiently large data set with which to formulate
hypotheses that could then be tested with more focused exper-
iments.
RESULTS
Time-Lapse Microscopy to Determine Cell Fate
To define how cancer cells respond to antimitotic drugs, we
devisedahigh-throughput time-lapsemicroscopyapproach, val-
idating it first using HeLa cells, a line commonly employed bymi-
tosis researchers.HeLacellswere transfectedwithaGFP-histone
H2B cDNA, and stable integrants were selected and pooled to
generate a polyclonal cell line. Cells were seeded into a 96-well
plate and then synchronized in early S phase using a thymidine
block (Figure 1A). After 4.5 hr following release from the block,
antimitotic agents were added, and fluorescence images were
acquired every 5 min for 72 hr. Image sequences were then ana-
lyzed, tracking 100 individual cells to determine their behavior.
In theabsenceofantimitoticdrugs,HeLacellsunderwentmultiple
mitoses with normal timings (see Figure S1 available online), indi-
cating that phototoxicity is not a limitation during the time course.
Within a few hours of drug addition, virtually all of the cells
entered mitosis, indicating release from the S phase block. The
majority of cells then arrested for a prolonged period before
undergoing one of two fates (Figure S2A). Some cells exited mi-
tosis without any signs of division and returned to interphase,
while others clearly died in mitosis (Figure 1B). Those that re-
turned to interphase exhibited one of three fates: some died in
interphase, others remained in interphase for the remainder of
the experiment, and others entered a second mitosis (Figure 1B;
Figure S2A). In addition to these main fates, a few other behav-
iors were apparent. Although rare, some cells separated their
chromosomes and divided (Figure 1B); this occurred more fre-
quently at low drug concentrations. In addition, some cells never
entered mitosis, remaining in interphase for the duration of the
experiment. Others died in interphase without entering mitosis
(Figure S2A).112 Cancer Cell 14, 111–122, August 12, 2008 ª2008 Elsevier Inc.Cancer Cells Display Complex Fate Profiles
The time-lapse analysis indicated that HeLa cells do not behave
in a uniform manner following prolonged mitotic arrest. There-
fore, to represent the data in a manner that facilitates compara-
tive analyses without obscuring the complexity, we plotted fate
profiles for each set of 100 cells (Figure 1C). In these profiles,
each horizontal line represents one cell, with the length of the
line corresponding to the duration of a given behavior and the
color of the line representing the behavior (see Figure S2B for
more details). When treated with 30 ng/ml nocodazole, eight
out of 100 HeLa cells arrested in mitosis for an average of
489 min, exited, then remained in interphase for the remainder
of the experiment (subpopulation a in Figure 1C). Fifty-five cells
arrested for a similar period and also exited but then endocycled,
entering second and third mitoses without ever dividing
(subpopulation b). Six cells arrested, exited, entered a second
mitosis, exited, and then died in the subsequent interphase
(subpopulation c). Thirteen cells died in interphase following
exit from their first mitosis (subpopulation d). Ten cells exited
and returned to interphase following the first mitosis but then
died in the secondmitosis (subpopulation e). Another six cells ar-
rested for about 768 min and then died in mitosis (subpopulation
f). Two cells died in interphase without entering mitosis (subpop-
ulation g).
The fate profile in Figure 1C clearly illustrates that when treated
with nocodazole, HeLa cells do not simply exhibit a singular cell
fate following prolonged mitotic arrest: although about 70% of
cells endocycle, other fates manifest, including death in mitosis
and death in interphase. We define this phenomenon as ‘‘intra-
line variation.’’ To determine whether complex fate profiles
occurred with other drugs, we analyzed the effects of taxol and
an Eg5 kinesin inhibitor, AZ138 (Figure S3). Whereas nocodazole
prevents spindle assembly by inhibiting microtubule polymeriza-
tion, taxol stabilizesmicrotubules and AZ138 blocks centrosome
separation. Once again, the profiles were complex, with multiple
fates manifesting (Figure 1C). However, in stark contrast to the
nocodazole profile, HeLa cells did not endocycle with these
drugs. With taxol, 73% of cells exited a prolonged mitotic arrest
and then died in the following interphase. With AZ138, 83% of
cells died in mitosis. Thus, although multiple fates are observed
with each drug, the proportion of cells exhibiting any given fate is
dramatically different. Together, these observations are striking,
revealing a complex situation not previously revealed by popula-
tion-based approaches.
Cancer Cells Display Profound Intraline
and Interline Variation
To determine how other types of cancer cells behave when
treated with antimitotic drugs, we selected a panel of seven
colon cancer lines, three of which (HCT116, DLD-1, and RKO)
display microsatellite instability (MIN) and four of which (HT29,
SW480, SW837, and LoVo) display chromosome instability
(CIN) (see Lengauer et al., 1997), plus a panel of five lung cancer
lines (A549, H226, Calu6, H2030, and H1703). All were
transfected with the GFP-histone H2B cDNA, and the resulting
polyclonal lines were analyzed in the presence of nocodazole,
taxol, and two Eg5 inhibitors, AZ138 and monastrol (Mayer
et al., 1999). For the two panels of lines, we used the minimal
drug concentration required to efficiently block cell division
Cancer Cell
How Cancer Cells Respond to Antimitotic Drugs(Figure S4). Fate profiles were constructed for all conditions, and
the full data set is presented in Figure S5. The level of complexity
is profound. Cells in most lines exhibited a variety of cell fates,
confirming the extensive intraline variation observed with
HeLa. In addition, different cell lines exhibited dramatically differ-
ent fate profiles with the same drug; we define this as ‘‘interline
variation.’’ The extent of this variation is illustrated by the MIN
lines in response to 0.1 mM taxol (Figure 2A). The majority of
DLD-1 cells arrested in mitosis and then returned to interphase,
with 37% of these remaining in interphase and 41% entering
Figure 1. Time-Lapse Microscopy to Determine Cell
Fate in Response to Antimitotic Agents
(A) Timeline showing experimental strategy.
(B) Examples of time-lapse sequences illustrating the fates ex-
hibited by HeLa cells following prolonged exposure to antimi-
totic drugs. See text for details. Scale bar = 10 mm. Numbers
indicate times in minutes.
(C) Fate profiles of HeLa cells exposed to 30 ng/ml nocoda-
zole, 0.1 mM taxol, and 1 mM AZ138.
a secondmitosis. Themajority of HCT116 cells also
exited mitosis after prolonged arrest, but 32% then
died in the subsequent interphase, a fate rarely ex-
hibited by DLD-1. In stark contrast, virtually all of
the RKO cells died in mitosis.
As outlined above, HeLa cells displayed dramat-
ically different fate profiles with the three types of
antimitotic drugs (Figure 1C). Similarly, the three
MIN lines had very different fate profiles with taxol
(Figure 2A). However, in contrast to HeLa, each
MIN line had a more uniform response to the differ-
ent drugs. For example, the majority of RKO cells
died in mitosis irrespective of the drug, as did the
CIN line HT29 (Figure S5). A549 provides another
example of a line that shows intraline variation but
less variation in response to the different drugs.
With nocodazole, taxol, or AZ138, the majority of
A549 cells exited mitosis without dividing, with
a significant fraction then dying in interphase;
very few cells endocycled or died in mitosis
(Figure 2B).
In some cases, the fate profiles changed dramat-
ically at different drug concentrations. At 200 ng/ml
nocodazole, most H226 cells died in mitosis, while
at 30 ng/ml, they tended to exit and return to inter-
phase (Figure S6). H2030 cells were also sensitive
to high concentrations of nocodazole, but in a dif-
ferent manner: at 200 ng/ml, most cells failed to
enter mitosis. Paradoxically, in terms of the mitotic
death phenotype, H1703 cells were more sensitive
to low doses of taxol: at 0.1 mM, almost all of the
cells died in mitosis, while at 10 mM, 63% returned
to interphase.
Cell Fate Is Not Necessarily Genetically
Predetermined
Numerous attempts have been made to identify
oncogenic lesions responsible for cell fate deci-
sions in individual lines (see Rieder and Maiato, 2004; Weaver
and Cleveland, 2005). By definition, such efforts assume that dif-
ferent fates are genetically predetermined. However, the intraline
variation revealed by our analysis argues that this is not neces-
sarily the case. Conceivably, however, the cells within each
line may not be genetically homogeneous, for example due to
genetic instability and/or different integration sites of the GFP re-
porter. To address this, we considered A549 cells, which typi-
cally exit mitosis (only 5% die in mitosis; Figure 2B). If these
two fates were due to two genetically distinct subpopulations,Cancer Cell 14, 111–122, August 12, 2008 ª2008 Elsevier Inc. 113
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likely mitotic exit. However, when three subclones were exposed
to nocodazole, all displayed complex fate profiles similar to the
parental line (Figure S7).
To further address this, we performed a pedigree analysis.
HCT116 cells were allowed to proceed through one mitosis in
the absence of antimitotic drug so that we could identify daugh-
ter cells derived from the same mother. We then added AZ138
and determined the fate of 50 pairs of sisters following prolonged
arrest (Figure 3). Of 12 cells that died in mitosis, only 2 sisters did
so; the remaining 10 sisters exited mitosis and returned to inter-
phase, clearly demonstrating that the fate of one sister is inde-
pendent of the fate of the other.
Next, we analyzed two nontransformed cell lines that lack
genomic instability and are therefore genetically more homoge-
neous (Kim et al., 2002). Significantly, human mammary
epithelial (HME) cells also underwent multiple fates following
prolonged mitotic arrest (Figure S8A). Similarly, RPE cells
Figure 2. Inter- and Intraline Variation
(A) Fate profiles of DLD-1, HCT116, and RKO cells following
exposure to 0.1 mM taxol.
(B) Fate profiles for A549 cells exposed to 30 ng/ml nocoda-
zole, 0.3 mM taxol, and 1 mM AZ138.
exhibited multiple fates, although their behavior
was more homogeneous compared to the HME
cells (Figure S5). Note that HME sister cells also
showed different fates in the pedigree analysis
(Figure S8D).
Taking together the complex fate profiles, the
fact that subclones yield complex profiles typical
of their parents, and the pedigree analyses, our
data argue that cell fate following prolongedmitotic
arrest is not determined exclusively by the genetic
makeup of that cell. This clearly has significant im-
plications for any attempts to define the genetic le-
sions responsible for dictating cell fate in response
to antimitotic agents.
Duration of Mitotic Arrest Does Not
Dictate Fate
It is widely assumed that the duration of mitotic ar-
rest dictates subsequent cell fate (Masuda et al.,
2003; Rieder and Maiato, 2004; Weaver and Cleve-
land, 2005; Tao et al., 2005). To test this notion, we
compared the mitotic arrest period of cells that ei-
ther died in mitosis or exited mitosis and returned
to interphase.While themean arrest time varied be-
tween lines and in response to different drugs, we
observed no correlation between the duration of
mitotic arrest and the subsequent cell fate. For ex-
ample, although HCT116 cells arrested longer with
taxol compared to nocodazole and AZ138, the du-
ration ofmitotic arrest was not significantly different
for cells that died inmitosis versus those that exited
and returned to interphase (Figure 4A). Of the
HCT116 cells that exited mitosis, some remained
in interphase for the remainder of the experiment, while others
died. Again, there was no correlation between the time spent
in mitosis and either of these postmitotic exit fates (Figure 4B).
Finally, of the three lines in which cells predominantly died in mi-
tosis, HT29 cells arrested for about 2000 min with nocodazole,
taxol, and AZ138, while RKO and H1703 arrested for much
shorter periods (Figure 4C). In summary, having analyzed 13 dif-
ferent cancer lines, we observed no obvious correlation between
the duration of the mitotic arrest and the subsequent cell fate.
Chromosome Instability Is Not a Result of an Impaired
Spindle Checkpoint
It is widely assumed that CIN cells have a defective or weakened
SAC (Cahill et al., 1998; Masuda and Takahashi, 2002; Draviam
et al., 2004; Weaver and Cleveland, 2005). Even though we pre-
viously showed that CIN cells do in fact arrest in response to
spindle damage (Tighe et al., 2001), it is still believed that the
SAC is somehow attenuated: although these cells arrest, they114 Cancer Cell 14, 111–122, August 12, 2008 ª2008 Elsevier Inc.
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we specifically measured the time cells spent arrested in mitosis.
Our data clearly show that when treated with nocodazole, taxol,
or AZ138, CIN cells arrested for as long as—and even longer
than, in some cases—the MIN cells (Figure 5A; Figure S9). CIN
cells also arrested for longer than the nontransformed HME
and RPE cells (Figure S5). The SAC is therefore clearly functional
in CIN cells that experiencemajor spindle damage. However, the
SAC is capable of delaying anaphase in response to a single un-
aligned chromosome (Rieder et al., 1995). Therefore, we ana-
lyzed 100 cells from each of three CIN and MIN lines in the ab-
sence of drug, scoring the number of cells that entered
anaphase with at least one chromosome not at the metaphase
plate. In only one line—which happened to be non-CIN—did
we observe a premature anaphase (Figures 5B and 5C). Note
that the time-lapse assay is capable of detecting premature ana-
phases; when we treated DLD-1 cells with a GSK3 inhibitor to
deliberately compromise the SAC (Tighe et al., 2007), we ob-
Figure 3. Cell Fate in Response to Antimitotic Drugs Is Not Geneti-
cally Predetermined
HCT116 mother cells (M) were followed through one mitosis in the absence of
drug to identify pairs of daughter cells (D1 and D2). AZ138 was then added,
and 50 daughter pairs were followed to determine their fate following the sec-
ond mitosis, as indicated. The numbers below the colored boxes indicate the
number of cells exhibiting that particular fate.served 12 premature events. Therefore, by the two working def-
initions of the SAC, namely the ability to arrest in response to
spindle damage and the ability to delay anaphase in response
to a single unaligned chromosome, these data clearly demon-
strate that the SAC is functional in CIN cells. Thus, the notion
that a weakened SAC accounts for the different fates exhibited
by different cancer lines is not supported.
Chromosome Instability Is Linked to Chromosome
Bridges
While a defective SAC cannot account for CIN, we were
struck by two differences between the MIN and CIN lines.
The first difference is that CIN cells frequently displayed chro-
mosome bridges at anaphase (Figures 5B and 5C), confirm-
ing a recent report (Thompson and Compton, 2008). There
is now compelling evidence that anaphase bridges arise be-
cause merotelic orientations (i.e., where one kinetochore is
attached to both spindle poles) are not resolved prior to ana-
phase onset (Cimini et al., 2001). Importantly, merotelic kinet-
ochores stably attach microtubules and therefore go unde-
tected by the SAC. Thus, we concur that the source of CIN
is not an attenuated SAC but more likely the inability to re-
solve merotelic orientations (Thompson and Compton,
2008). The second difference is that while both CIN and
MIN cells arrest efficiently in 1 mM AZ138, only the MIN cells
mounted a robust checkpoint response in 100 mM monastrol.
By contrast, many of the CIN cells divided (Figure 5A). This
presents a paradox: if the SAC is functional in CIN cells,
why do they not arrest efficiently in monastrol?
The observation that CIN cells cannot resolve merotelics pro-
vides an explanation. Compared to AZ138, monastrol is not as
potent an inhibitor of Eg5 (Figure S3); rather than a total block
on centrosome separation, it therefore appears that spindles
can eventually bipolarize in monastrol, allowing division
(Figure 5A). Because malorientations are more likely to arise fol-
lowing mitotic delay (Cimini et al., 2001), merotelics are probably
present despite the spindle bipolarizing. InMIN cells, we suggest
that this gives rise to rounds of microtubule capture and release,
thus continually generating unattached kinetochores and main-
taining SAC-mediated mitotic arrest. By contrast, the inabilityFigure 4. Duration of Mitotic Arrest Does Not Dictate
Fate
Box-and-whisker plots show the time that cells spent arrested
in mitosis as a function of subsequent cell fate following expo-
sure to nocodazole (N), taxol (T), or AZ138 (A). The boxes show
the mean and the interquartile ranges, while the whiskers
show the full range.
(A) HCT116 cells that either died in mitosis (red) or exited
mitosis and returned to interphase (blue).
(B) HCT116 cells that returned to interphase and then either
died in interphase (green) or remained in interphase for the
rest of the experiment (gray).
(C) RKO, HT29, and H1703 cells that died in mitosis.Cancer Cell 14, 111–122, August 12, 2008 ª2008 Elsevier Inc. 115
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kinetochores are not generated. The SAC therefore becomes
satisfied, permitting cell-cycle progression. Consistent with this
hypothesis, colon cancer cells can form bipolar spindles in the
presence of monastrol (Figure S10B). Furthermore, kinetochores
on bipolar spindles in monastrol-treated DLD-1 cells (MIN)
stained strongly for Bub1, consistent with malorientations and
checkpoint activation (Figure S10C). By contrast, kinetochores
in HT29 and SW480 cells (both CIN) stained weakly for Bub1.
This hypothesis predicts that at a low concentration of AZ138,
yielding a level of Eg5 inhibition equivalent to that achieved
with 100 mM monastrol, the MIN-CIN differential should also
manifest. Indeed, at 0.03 mMAZ138, the MIN cells arrested while
the CIN cells frequently divided (Figure 5A; see also Figure S10).
Figure 5. CIN Cells Have a Functional
Spindle Checkpoint
(A) Fate profiles of three microsatellite instability
(MIN) lines (DLD-1, HCT116, and RKO) and three
chromosome instability (CIN) lines (HT29,
SW480, and SW837) in response to 1 mM AZ138,
0.03 mM AZ138, and 100 mM monastrol.
(B) Frequency of premature anaphases and ana-
phase bridges in MIN and CIN cells. SB4 denotes
the GSK3 inhibitor SB-415286.
(C) Time-lapse sequences showing a normal mito-
sis in DLD-1 cells, a premature anaphase in SB4-
treated DLD-1 cells, and an anaphase bridge in
HT29 cells (arrowhead). The asterisks indicate un-
aligned chromosomes. The numbers represent
time in minutes, with t = 0 being the first frame
showing signs of anaphase chromosome move-
ment. Scale bar = 10 mm.
Although many CIN cells divide follow-
ing low-penetrance Eg5 inhibition, they
probably do so aberrantly: while 64% of
untreated HT29 cells completed three di-
visions within 72 hr (data not shown), only
8% did so in 0.03 mM AZ138 (Figure 5A).
In addition, the majority of SW480 cells
arrested after their first division in the
presence of AZ138. While this raises the
possibility that CIN cells may be more
sensitive to transient Eg5 inhibition, it is
not because they have an attenuated
SAC but because they cannot resolve
malorientations.
Cell Fate and the Spindle
Checkpoint
Several reports argue that the different
fates of CIN cells following prolonged mi-
totic arrest arise due to differences in
SAC status (Kasai et al., 2002; Wang
et al., 2003; Vogel et al., 2004; Lee et al.,
2004; Sudo et al., 2004; Tao et al.,
2007). However, as we show, the SAC is
not defective in CIN cells. This is not to
say that the SAC is not required for the
long-term response to antimitotic drugs; artificially attenuating
the SAC in HeLa cells does alter the postmitotic response
(e.g., Taylor and McKeon, 1997). Indeed, whether a cell dies in
mitosis or dies in the subsequent interphase, the SAC is required
(Figure S11). When treated with taxol, DLD-1 cells typically exit
mitosis and arrest in interphase while HT29 cells die in mitosis.
However, when we attenuated the SAC using the Aurora B inhib-
itor ZM447439 (Ditchfield et al., 2003), virtually all of the cells in
both lines endocycled (Figure S11). Thus, both death in mitosis
and the postmitotic response require SAC function. This does
not, however, imply that the SAC ‘‘talks’’ directly to the signaling
pathways that cause mitotic death or control postmitotic cell
fate, as is often suggested (e.g., Shin et al., 2003; Niikura et al.,
2007). The simplest explanation is that prolonged mitotic116 Cancer Cell 14, 111–122, August 12, 2008 ª2008 Elsevier Inc.
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pathways. A key question, therefore, is how prolonged mitotic
arrest activates the cell death machinery.
Death in Mitosis Is Caspase Dependent
It was recently reported that mitotic death of HeLa cells ex-
posed to antimitotic drugs is caspase independent (Niikura
et al., 2007). To determine whether this is true for other can-
cer cells, we determined the fate profiles for HCT116, RKO,
HT29, and Calu6 cells in the presence of antimitotic drugs
plus a pan-caspase inhibitor. In all cases, the caspase inhib-
itor shifted the fate profile, reducing the number of cells that
died in mitosis in favor of cells that exited and returned to in-
terphase (Figure S5). For example, in the presence of AZ138,
57 HCT116 cells died in mitosis; upon caspase inhibition, this
was reduced to 12 (Figure 6A). HT29 cells typically die in mi-
tosis with all antimitotic drugs. Upon caspase inhibition, the
majority of HT29 cells exited mitosis and returned to inter-
phase (Figure S5). Thus, caspase-independent mitotic cell
death does not appear to be a universal feature of cancer
cells. Strikingly, caspase inhibition often prolonged the dura-
tion of the mitotic arrest. Mitotic cell death in HCT116 cells
exposed to AZ138 occurred, on average, after 761 ± 62 min
(Figure 6B). This was extended to 1627 ± 57 min in the pres-
ence of the caspase inhibitor. Likewise, cells that returned to
interphase also spent longer in mitosis when treated with the
caspase inhibitor (Figure 6B). However, for those cells that
exited mitosis and then died in interphase, the caspase inhib-
itor did not prolong the time between mitotic exit and cell
death (Figure 6B). HME cells behaved similarly when treated
with the caspase inhibitor (Figures S8B and S8C).
Delaying Slippage Shifts the Fate Profile
to Death in Mitosis
The observation that cyclin B1 is slowly degraded in RPE cells
during a prolonged mitosis has led to the suggestion that verte-
brate cells ‘‘slip’’ but do not ‘‘adapt’’ (Brito and Rieder, 2006).
However, because caspase inhibition extends the arrest time
and shifts the fate profile (Figure 6), cyclin B1 degradation cannot
be the only mechanism at play here. Rather, we speculated that
cell fate is dictated by two competing but independent mecha-
nisms, one involving caspase activation, the other protecting cy-
clin B1 from degradation. Thus, by slowing down caspase acti-
vation, mitotic cell death in HCT116 cells is delayed, and thus
the cells stay inmitosis for longer. During this time, cyclin B1 con-
tinues to be slowly degraded, eventually allowing slippage. In
other words, delaying apoptosis allows more time for slippage.
If this is the case, the converse should also be true: delaying slip-
page should allow more time for death signals to accumulate.
To test this, we generated a DLD-1 cell line expressing either
GFP or GFP-tagged cyclin B1 (Figure S12A). Whereas GFP
was relatively stable during an unperturbed mitosis, GFP-cyclin
B1 was degraded prior to anaphase, validating it as a slippage
marker (Figure 7B). Consistent with delaying slippage, overex-
pression of GFP-cyclin B1 extended the duration that cells ar-
rested in mitosis when challenged with AZ138 (Figure 7A). Strik-
ingly, the fate profile also shifted markedly: whereas only 6 cells
expressing GFP died in mitosis, 54 cells expressing GFP-cyclinB1 did so (Figure 7A). Thus, delaying slippage does indeed pro-
vide more time to accumulate death signals.
Cells that Die in Mitosis Do Not Breach
the Exit Threshold
Our observations are consistent with the notion that delaying
caspase activation allows more time for slippage (Figure 6)
and that, conversely, delaying cyclin B1 degradation allows
more time for death signals to accumulate (Figure 7A). This pro-
vides a possible explanation for intraline variation. Perhaps cells
that exit do so because cyclin B1 falls below the threshold re-
quired to maintain mitosis before sufficient death signals accu-
mulate. Conversely, cells that die in mitosis accumulate
Figure 6. Death in Mitosis Is Caspase Dependent
(A) Fate profiles of HCT116 cells treated with 1 mM AZ138 without or with the
pan-caspase inhibitor Boc-D-FMK.
(B) Box-and-whisker plots showing the time in mitosis (left panel) and time in
interphase (right panel) as a function of subsequent cell fate. The left panel
shows HCT116 cells that either died in mitosis (red) or exited mitosis and re-
turned to interphase (blue). The right panel shows the duration of interphase
after mitotic exit and before subsequent cell death (green). The boxes show
the mean and the interquartile ranges, while the whiskers show the full range.Cancer Cell 14, 111–122, August 12, 2008 ª2008 Elsevier Inc. 117
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(A) Left panel: fate profiles of DLD-1 cells expressing either GFP or GFP-tagged cyclin B1. Right panel: box-and-whisker plots showing that expression of GFP-
cyclin B1 extends the duration of mitotic arrest in response to AZ138. The boxes show the mean and the interquartile ranges, while the whiskers show the full
range.
(B) Degradation kinetics of GFP-cyclin B1 during an unperturbed mitosis. t = 0 marks nuclear envelope breakdown, and dashed vertical lines indicate anaphase
onset. The graph shows the mean fluorescence from six cells ± SEM.
(C) Fluorescence intensities of DLD-1 cells expressing GFP-cyclin B1 that either died in mitosis (red) or exited (blue) in the presence of 1 mM AZ138. Values rep-
resent the mean of six cells.
(D) Degradation kinetics of mCherry (white symbols) or mCherry D box (black symbols) during unperturbed mitoses in DLD-1 (squares), HT29 (circles), and RKO
(triangles). t = 0 marks nuclear envelope breakdown. The graph shows the mean fluorescence from five cells.
(E) Fluorescence intensities of DLD-1, HT29, and RKO cells expressing an mCherry D box fusion. Values represent the mean of six cells.sufficient death signals before cyclin B1 levels reach the thresh-
old. To test this, we quantitated GFP-cyclin B1 signal intensity in
six DLD-1 cells that exited in the presence of AZ138 and six that
died in mitosis. Note that in the absence of drug, anaphase oc-
curred when GFP-cyclin B1 levels fell to 32% (Figure 7B), de-
fining the threshold. In cells that died in mitosis, GFP-cyclin B1
levels fell to 51%, while in those that exited, it fell to 30%.
(Figure 7C). Thus, cells that exit mitosis do so because cyclin
B1 levels breach the mitotic exit threshold. By contrast, in cells
that die in mitosis, cyclin B1 levels do not fall below the mitotic
exit threshold.118 Cancer Cell 14, 111–122, August 12, 2008 ª2008 Elsevier Inc.In turn, these observations may help explain interline varia-
tion. Perhaps in lines that predominantly die in mitosis, such
as RKO and HT29, the level of cyclin B1 never approaches
the mitotic exit threshold. To test this, we generated RKO,
HT29, and DLD-1 lines expressing cyclin B1’s D box fused to
mCherry (Figure S12B). This allowed us to monitor cyclin deg-
radation without elevating Cdk1 activity. In the absence of
drug, mCherry D box levels in RKO and HT29 cells fell to
45% by anaphase onset (Figure 7D), thus defining the thresh-
old required for mitotic exit. In DLD-1 cells, the threshold was
slightly higher at 60%. Significantly, when treated with
Cancer Cell
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in RKO cells before these cells died (Figure 7E). Thus, in these
two lines, cyclin B1 degradation is slow and does not approach
the threshold required for mitotic exit. By contrast, DLD-1 cells
degraded the mCherry D box much faster, its level falling to
53% in under 400 min (Figure 7E), explaining their tendency
to exit mitosis.
DISCUSSION
Our analysis reveals a level of complexity that is at first over-
whelming. While some degree of interline variation was antici-
pated, it is striking that cells within a line can exhibit multiple
fates. This intraline variation does not appear to be genetically
predetermined, because sisters can undergo different fates. De-
spite the complexity, we can rule out two preexisting hypothe-
ses. First, cell fate does not correlate with the duration of mitotic
arrest. Second, cell fate is not determined by differences in the
status of the spindle checkpoint. More importantly, delaying cas-
pase activation or delaying cyclin B1 degradation dramatically
alters the fate profiles, allowing us to formulate a model
explaining both intra- and interline variation.
The Perils of Population Analyses
The intraline variation exposed here provides an explanation as
to why population-based studies lead to vague and confusing
interpretations (Rieder andMaiato, 2004). Sensitive immunoblot-
ting techniques can easily detect activation of a particular signal-
ing pathway, even if only a small fraction of cells within the pop-
ulation have triggered that pathway. This subpopulation may be
obscured in a complex flow cytometry profile, resulting in errone-
ous correlations between DNA content histograms and molecu-
lar events measured on blots. By contrast, time-lapse tracking of
individual living cells has allowed us to directly correlate mitotic
arrest times and cell fate. Clearly, our approach is not entirely
noninvasive, and it is conceivable that the GFP imaging proce-
dure affects cellular behavior. However, phototoxicity does not
appear to be limiting (Figure S1). Furthermore, bright-field imag-
ing and flow cytometry-based experiments (data not shown)
support the data described here. In addition, a comprehensive
single-cell immunofluorescence-based study reveals a level of
complexity consistent with that described here (Shi et al., 2008).
Cell Fate Is Dictated by Competing Networks
Having exposed the true extent of the variation exhibited by cells
in response to antimitotic agents, only now canwe start to devise
meaningful hypotheses. First, however, we need to define sev-
eral terms. We will use ‘‘slippage’’ to describe the process by
which a cell exits a prolongedmitotic arrest when cyclin B1 levels
fall below the threshold required to maintain the mitotic state
(Brito and Rieder, 2006). To describe the process by which
a cell activates a death pathway while still in mitosis, we will
use the phrase ‘‘death in mitosis.’’ To describe cell-cycle arrest
and/or apoptosis of interphase cells following slippage, we will
use the term ‘‘postmitotic response.’’ Accordingly, efficient entry
into a new cell cycle following slippage indicates the lack of a
robust postmitotic response.
We propose that cell fate is dictated by two competing but
independent networks, one involving activation of cell deathpathways, the other protecting cyclin B1 from degradation (Fig-
ure 8). During prolonged mitotic arrest, these two networks work
in opposite directions: while cell death signals become stronger,
cyclin B1 levels fall. We suggest that both networks have thresh-
olds and that the fate of the cell is dictated by which threshold is
breached first. Thus, if cyclin B1 levels fall below the mitotic exit
threshold first, slippage occurs (Figure 8A). If the death threshold
is breached first, the cell dies in mitosis.
This model helps explain both intra- and interline variation. Al-
though the genetic background of a particular cell line places
limits on rates and thresholds, for cells within any given line, net-
work stability will vary from cell to cell. Consequently, rates of cy-
clin B1 degradation and caspase activation probably occupy
broad ranges (Figure 8B). Because the two competing networks
are independent, the first threshold breached may therefore vary
from cell to cell, thus explaining intraline variation. With respect
to interline variation, for lines whose cells predominantly die in
mitosis, e.g., HT29 and RKO, differences in genetic background
result in relatively slow rates of cyclin B1 degradation, and thus
the cell death threshold is invariably breached first (Figure 8C).
However, cell death signals may accumulate faster in RKO com-
pared to HT29, accounting for different durations of mitotic ar-
rest before death. By contrast, in a line where cells rarely die in
mitosis, e.g., DLD-1, the mitotic exit threshold is invariable
breached first (Figure 8C).
A key issue now is to determine the molecular parameters
governing network output, namely the rates and thresholds.
Although silencing of the SAC triggers cyclin B1 degradation
during a normal mitosis, the SAC is only part of the network
controlling cyclin B1 degradation during a protracted mitosis;
Figure 8. Model Explaining Intra- and Interline Variation
(A) Death in mitosis versus slippage.
(B) Intraline variation.
(C) Interline variation.Cancer Cell 14, 111–122, August 12, 2008 ª2008 Elsevier Inc. 119
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SAC such as the balance of ubiquitination and deubiquitination
of cyclin B1. Factors influencing caspase activation during mi-
tosis are less well understood, but a key player could be cas-
pase-9, which was recently shown to be phosphorylated by
Cdk1 in order to restrain apoptosis during mitosis (Allan and
Clarke, 2007). Our model is consistent with Allan and Clarke’s
notion that death in mitosis may be induced by the slow net de-
phosphorylation of caspase-9. The nature of the damage signal
is still elusive. One possibility is that DNA damage slowly accu-
mulates during a protracted mitosis that, in the absence of ef-
ficient repair, eventually activates intrinsic apoptotic pathways.
Drug-Dependent and Concentration-Dependent
Variation
Our model accounts for variation with respect to whether a cell
dies in mitosis or exits and returns to interphase. It does not,
however, explain why HeLa cells for example display different
fate profiles with different drugs. Recently, the phosphorylation
status of the anaphase-promoting complex/cyclosome (APC/C),
purified from HeLa cells, has been determined by quantitative
mass spectroscopy (Steen et al., 2008). The APC/C, an E3 ubiq-
uitin ligase responsible for targeting cyclin B1 for degradation
and thus triggering mitotic exit, is the downstream target of the
SAC (Musacchio and Salmon, 2007). Interestingly, the phos-
phorylation profiles vary depending on the antimitotic drug
used to arrest the cells in mitosis (Steen et al., 2008). The reason
for this is unclear but could involve differential effects on micro-
tubule dynamics and/or polymer levels. The different fate profiles
exhibited by HeLa cells may therefore be due to differential
APC/C phosphorylation. In addition, the spectrum of APC/C
phosphorylation may depend on drug concentration, explaining
why the fate of some lines varies at different drug concentrations
(Figure S5). If differential APC/C phosphorylation does indeed
dictate fate, then lines that behave similarly with different drugs
and/or at different concentrations should have more uniform
APC/C phosphorylation profiles. While experiments testing
these predictions will not be straightforward, they may provide
critical insight into the mechanisms dictating the rate of cyclin
B1 degradation during a protracted mitosis.
The Postmitotic Response
Another aspect of variation not immediately covered by our
model is cell fate following slippage, i.e., the postmitotic re-
sponse. The factors at play here remain obscure, and it is not
even clear whether the postmitotic response is a delayed reac-
tion to damage incurred during mitosis or whether returning to
interphase without successfully dividing creates a de novo dam-
age signal. The concept of a ‘‘tetraploidy checkpoint’’ assumes
that an aberrant division creates a de novo damage signal,
namely tetraploidy (Andreassen et al., 2001). However, it is im-
portant to note that cell division failure is not sufficient to provoke
a postmitotic response: artificially abrogating the SAC in the
presence of antimitotic drugs causes cell division to fail, yet
the cell cycle continues (Taylor and McKeon, 1997). Indeed,
the ‘‘tetraploidy checkpoint’’ concept is no longer favored, as
the cell-cycle arrest observed can be accounted for by drug-in-
duced DNA damage (Uetake and Sluder, 2004). Thus, the post-
mitotic response may simply be a delayed reaction to damage120 Cancer Cell 14, 111–122, August 12, 2008 ª2008 Elsevier Inc.incurred during mitosis. If this is the case, then two additional
observations allow our model to be extended to account for
the postmitotic variation. First, the time between mitotic exit
and death in interphase was variable and did not correlate with
time spent in mitosis (Figure 4B). Second, the caspase inhibitor
did not extend the gap between mitotic exit and subsequent ap-
optosis (Figure 6B). It is therefore possible that in some cells, suf-
ficient damage accumulates during mitosis to initiate apoptosis
but execution is delayed. Because the networks governing slip-
page and death in mitosis are not linked, cyclin B1 degradation
continues regardless, allowing some cells to slip out of mitosis
prior to executing the apoptotic program. Apoptosis would man-
ifest in the subsequent interphase at a time linked to initiation but
not to mitotic exit.
Note that we do not exclude the possibility that there is a sep-
arate postmitotic response. We previously showed that p53 is
required to restrain endocycling when cells exit mitosis in the
presence of an Aurora B inhibitor (Ditchfield et al., 2003). In this
case, although cell division fails, mitotic exit is delayed only
briefly; there is no protracted mitotic arrest. It seems unlikely
that this brief delay is sufficient for damage signals to accumu-
late to a level high enough to trigger a response, strongly sug-
gesting that there is indeed a separate, p53-dependent postmi-
totic response.While the nature of the damage signal is elusive, it
is not clear to us that there is any evidence for a de novo trigger. It
has been suggested that p53 is activated during a prolonged mi-
totic arrest (Vogel et al., 2004), but there is no direct evidence for
this. In our experiments, while inhibiting p53 allowedmore endo-
cycling, it did not protect against mitotic death (Figure S13). One
possibility is that even minor perturbations during mitosis induce
DNA damage or other forms of cellular stress that, while insuffi-
cient to trigger death in mitosis, may be sufficient to activate p53
and/or other responses in the subsequent interphase. The cas-
pase-9 data provide insight here (Allan and Clarke, 2007): per-
haps mitosis-specific events, such as caspase-9 phosphoryla-
tion, raise a threshold that allows minor insults to be ignored.
Upon return to interphase, the threshold is lowered, e.g., by cas-
pase-9 dephosphorylation, allowing the damage to be sensed. If
this is the case, the postmitotic response need not be any differ-
ent from the normal interphase mechanisms that respond to cell
stresses.
Future Directions
The analysis described here illustrates that high-throughput
time-lapse approaches offer advantages over less direct ap-
proaches. However, this type of analysis is currently limited be-
cause there are few bioprobes capable of monitoring molecular
events in living cells. Developing such tools will be essential in or-
der to decode the mechanisms that dictate cell fate in response
to antimitotic agents.
EXPERIMENTAL PROCEDURES
Cell Lines and Drugs
Lung carcinoma lines (A549, H226, Calu6, H2030, and H1703) and colon car-
cinoma lines (DLD-1, HCT116, RKO, HT29, SW480, SW837, and LoVo) were
obtained from the American Type Culture Collection. hTERT-HME and
hTERT-RPE were from Clontech, and TA-HeLa cells were as described previ-
ously (Taylor and McKeon, 1997). All cancer lines and hTERT-RPE were cul-
tured in DMEM plus 10% fetal calf serum (GIBCO), 2 mM glutamine, 100 U/ml
Cancer Cell
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cultured in mammary epithelial growth medium (Lonza). All lines were grown
at 37C in a humidified 5% CO2 incubator. Small molecules dissolved in
DMSO were used at the following concentrations unless stated otherwise: no-
codazole (Sigma) 30 ng/ml, taxol (Sigma) 0.1 mM, AZ138 (AstraZeneca) 1 mM,
monastrol (Sigma) 100 mM, SB-415286 (Calbiochem) 30 mM, ZM447439 (Toc-
ris) 2 mM, Boc-D-FMK (Calbiochem) 100 mM. Thymidine dissolved in water was
used at 2 mM.
Retroviral Infections and Transfections
A GFP-tagged histone H2B cDNA (Morrow et al., 2005) cloned into a pLPCX-
based vector (Clontech) was introduced into all of the cell lines using retrovi-
rus-mediated transduction as described previously (Hussein and Taylor,
2002). Stably transduced cells were selected in puromycin, and colonies
were pooled and expanded to create polyclonal cell lines. cDNAs encoding
the N-terminal 90 amino acids of cyclin B1 fused to mCherry and p53 (wild-
type and V143A) were cloned into a pLNCX2-based vector (Clontech) modified
to contain an N-terminal Myc tag, then similarly transduced into cells followed
by selection in G418. Isogenic DLD-1 cells expressing GFP-tagged cyclin B1
under tetracycline control were generated using FRT-Flp-based recombina-
tion as described previously (Tighe et al., 2004).
Time-Lapse Imaging
Cells were seeded in 96-well mClear plates (Greiner) at 1.33 104 cells per well
in a volume of 200 ml. Eight hours later, thymidine was added for 16 hr. Cells
were then washed three times in PBS and released in 100 ml of fresh medium
for 4.5 hr before addition of drugs in another 100 ml of medium. Imaging was
performed using a Pathway Bioimager 855 (BD biosciences) with a 203/
0.30 UPlan FLN objective, with images collected every 5 min using a 0.1 s
exposure. Image sequences were viewed using NIH ImageJ software (http://
rsbweb.nih.gov/ij/), and cell behavior was analyzed manually. For pedigree
analysis, cells were imaged in drug-freemedium for 16 hr; drug-containingme-
dium was then added, and image acquisition was continued for a further 72 hr.
To monitor chromosome segregation in the absence of drug and to quantitate
degradation of fluorescently tagged fusions, cells were seeded in 24-well
plates (Corning) at 33 104 cells per well and then synchronized with thymidine
as above. After drug addition, image acquisition was performed using a Zeiss
Axiovert 200-based system as described previously (Morrow et al., 2005).
Images were collected every 5 min using a 323 Apoplan objective. Image
sequences were viewed and integrated pixel intensity measurements were
performed using ImageJ.
SUPPLEMENTAL DATA
The Supplemental Data include thirteen figures and can be found with this
article online at http://www.cancercell.org/cgi/content/full/14/2/111/DC1/.
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